/p>According to the scientific evidence presented in the observational study No-Painprepared by the laboratory Procare Health and presented during the celebration of the EFORT European Congress (European Federation of National Associations of Orthopedics and Traumatology), three months after a single injection of Pronolis HD Mono 2.5% patients with primary knee osteoarthritis they improve the pain generated, joint stiffness, functional capacity and, ultimately, their quality of life. Specifically, it has been observed average pain reduction of 54.5%average reduction of pain when moving 56% and an average reduction of stiffness of 62.87%.
The person in charge of explaining the benefits of this new treatment was the Dr Monforthead of the Osteoarthritis Unit of the Rheumatology Service of the Barcelona Sea Hospital during the presentation “High Density Hyaluronic Acid in the treatment of Primary Osteoarthritis: Clinical Results and Clinical Practice”.
The study is an open-label, prospective, multicenter, observational, real-life analysis that aims to to measure the evolution of pain in patients diagnosed with primary knee osteoarthritis and who are treated with a single injection of (120mg HA in a 4.8 mL syringe).
This product, which was launched on the market last September, is the First High Density Hyaluronic Acid (HA) in a completely new range of viscosupplementation of intra-articular injections for the treatment of osteoarthritis.
“There is evidence that the molecular weight and, to a greater extent, the concentration of HA have a direct effect on the viscosity of the synovial fluid. For this reason, both physical characteristics, especially concentration, influence the behavior of AH”, explains Dr. Monfort.
Pronolis HD is a class III medical device that consists of a sterile viscoelastic solution of HA, the viscosupplement with the highest concentration of HA currently available on the market. In addition, the wide range of concentrations of Pronolis HD (1%, 1.6%, 2.2% and 2.5%), allows a stepped and individualized treatment of the patient and of all kinds of synovial joints: knee, hip, hands (wrist and fingers), feet, ankle, shoulder, etc.
In line with its objective of promoting scientific research and improving the well-being of patients, has launched the study No-Pain. This analysis foresees the recruitment of 300 patients with knee osteoarthritis by 60 health professionals with a follow-up of six months after the injection of the product.
The research will allow observe the evolution of pain and quality of life of patients through internationally validated questionnaires (WOMAC and EQ-5D-5L) in addition to the safety of the product.